Daewon Pharmaceutical Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1958-01-07
- Employees
- 1.2K
- Market Cap
- -
- Website
- http://www.daewonpharm.com
Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT03874260
- Locations
- 🇰🇷
Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Korea, Republic of
To Evaluate the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 462
- Registration Number
- NCT03443804
A Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of DW340 in Patients With Acute Low Back Pain
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT03424707
Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 352
- Registration Number
- NCT03221907
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 129
- Registration Number
- NCT03210532
- Locations
- 🇰🇷
Sevrance Hospital, Seoul, Korea, Republic of
Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 71
- Registration Number
- NCT02933658
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the Knee
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 191
- Registration Number
- NCT02682524
- Locations
- 🇰🇷
Inha university hospital, Chung gu, Incheon, Korea, Republic of
Phase â…£ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT02681991
- Locations
- 🇰🇷
Gangnam Sevrance Hospital of Yonsei University, Seoul, Gangnam-gu, Korea, Republic of
A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 153
- Registration Number
- NCT02681952
- Locations
- 🇰🇷
Sevrance Hospital of Yonsei University, Seoul, Seodaemun, Korea, Republic of
Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2016-10-10
- Lead Sponsor
- Daewon Pharmaceutical Co., Ltd.
- Target Recruit Count
- 348
- Registration Number
- NCT02390375
- Locations
- 🇰🇷
Boramae Hospital, Seoul, Dongjak-gu, Korea, Republic of
© Copyright 2024. All Rights Reserved by MedPath